The extended cash runway to Q4 2028 and accelerated Phase 3 enrollment reduce near-term financing risk, but the widening loss and heavy R&D spend are typical for a late-stage biotech. The key catalyst to watch is the Phase 2 pancreatic data update in 1H 2027 and any further acceleration of the Phase 3 topline readout.
Price Chart
Executive Summary
Immuneering reported Q3 2026 net loss of $24.2M ($0.37 per share), wider than the $15.0M loss a year ago, as R&D spending nearly doubled to $20.7M to support the expanded Phase 3 MAPKeeper 301 trial and Phase 2 pancreatic cancer extension. The company highlighted that Phase 2 follow-up is being extended because patients are living longer than projected, and Phase 3 enrollment is ahead of schedule, enabling a potential acceleration of the mid-2028 topline readout. Cash runway guidance was updated to Q4 2028, reflecting the expanded clinical activities.
Key Financial Metrics
Key Facts
- Q3 2026 net loss of $24.2M ($0.37 per share) vs $15.0M ($0.38 per share) in Q3 2025
- R&D expenses $20.7M in Q3 2026, up from $10.9M in Q3 2025, driven by higher clinical costs for lead program and personnel
- Cash, cash equivalents and marketable securities $166.1M as of Sep 30, 2026, down from $217.0M at Dec 31, 2025
- Cash runway guidance updated to Q4 2028, reflecting Phase 2 extension, accelerated/expanded Phase 3 enrollment, and commercial readiness activities
- Phase 2 pancreatic cancer trial follow-up extended because patients are living longer than projected; updated data expected 1H 2027
- Phase 3 MAPKeeper 301 enrollment ahead of schedule; enrollment target expanded from 510 to 570 patients; potential to accelerate mid-2028 topline data readout
- Atebimetinib featured on cover of Cancer Research in October 2026, highlighting its broad preclinical activity and favorable tolerability
- Preclinical data for atebimetinib + anti-PD-1 in lung cancer expected at SITC in Q4 2026; Phase 2 lung cancer trial dosing first patient in Q4 2026
Financial Impact
Net loss widened by $9.2M YoY; cash burn of $50.9M in 9 months; cash runway extended to Q4 2028
Risk Factors
- Net loss widening and cash burn rate of ~$18M per quarter could pressure runway if enrollment or timelines slip
- Phase 3 MAPKeeper 301 topline data not expected until mid-2028 at earliest, leaving a long period without major catalysts
- Phase 2 pancreatic data update in 1H 2027 is based on extended follow-up; positive survival trends may not persist in larger Phase 3
- Competitive landscape for pancreatic cancer treatments remains intense
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3391832 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | No price | awaiting T+1 | awaiting T+1 | No price |
Oct 29, 2026 3d ago | Press Release | $4.02 | awaiting T+1 | awaiting T+1 | $3.74 (−6.84%) |
Oct 26, 2026 6d ago | Press Release | $3.71 $3.83 | ▲ +3.23% | ▲ +2.67% | $3.74 (+0.94%) |
Oct 2, 2026 4w ago | Press Release | $4.07 $4.04 | ▼ −0.74% | ▼ −1.41% | $3.74 (−7.99%) |
Sep 28, 2026 4w ago | Press Release | $4.16 $4.13 | ▼ −0.72% | ▼ −0.54% | $3.74 (−9.98%) |
Aug 26, 2026 9w ago | Press Release | $5.21 $4.99 | ▼ −4.22% | ▼ −4.00% | $3.74 (−28.12%) |
Aug 5, 2026 12w ago | 8-K | No price | awaiting T+1 | awaiting T+1 | No price |
Aug 5, 2026 12w ago | Press Release | $4.39 $4.46 | ▲ +1.59% | ▲ +1.75% | $3.74 (−14.69%) |
Jun 11, 2026 20w ago | Institutional Cluster | $4.12 $4.19 | ▲ +1.70% | ▲ +1.16% | $3.74 (−9.10%) |
Jun 1, 2026 21w ago | 8-K | $4.28 $4.55 | ▲ +6.31% | ▲ +7.00% | $3.74 (−12.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers